New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - roxithromycin 50mg - tablet - 50 mg - active: roxithromycin 50mg excipient: colloidal silicon dioxide glucose hypromellose   hypromellose phthalate magnesium stearate maize starch poloxamer povidone propylene glycol purified talc

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - roxithromycin 50mg - dispersible tablet - 50 mg - active: roxithromycin 50mg excipient: colloidal silicon dioxide crospovidone strawberry fumaric acid glycyrrhiza glabra macrogol 6000 magnesium stearate methacrylic acid copolymer microcrystalline cellulose purified talc saccharin sodium sodium hydroxide sodium laureth sulfate triethyl citrate

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

hexal pharma (sa) (pty) ltd - tablet - see ingredients - each tablet contains roxithromycin 150,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

hexal pharma (sa) (pty) ltd - tablet - see ingredients - each tablet contains roxithromycin 300,0 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - roxithromycin -

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - roxithromycin -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - roxithromycin -

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - clarithromycin 50 mg/ml;   - granules for oral suspension - 250 mg/5ml - active: clarithromycin 50 mg/ml   excipient: carbomer castor oil citric acid monohydrate hydrated silica hypromellose phthalate fruit mix flavour maltodextrin potassium sorbate povidone sucrose titanium dioxide xanthan gum - klacid suspension is indicated for treatment of infections caused by susceptible organisms. such infections include: ? upper respiratory infections (e.g. streptococcal pharyngitis). ? lower respiratory infections (e.g. bronchitis, pneumonia). ? acute otitis media. ? skin and skin structure infections (e.g. impetigo, folliculitis, cellulitis, abscesses). ? disseminated or localized mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localised infections due to mycobacterium chelonae, mycobacterium fortuitum or mycobacterium kansasii.

Namibia - English - Namibia Medicines Regulatory Council

aventis pharma (pty) ltd - roxithromycin - tablet - 150 mg roxithromycin per tablet

Namibia - English - Namibia Medicines Regulatory Council

cipla medpro (pty) ltd - roxithromycin - tablet - each tablet contains roxithromycin 150,0 mg